10-Q: Relmada Shifts Focus, Reports Q2 Loss Amid Pipeline Revamp

Relmada Therapeutics reports a reduced net loss in Q2 2025, driven by strategic pipeline changes including new acquisitions and program terminations, but faces significant liquidity challenges and a Nasdaq compliance extension.

Summary

• Relmada Therapeutics, a clinical-stage biotechnology company, reported a net loss of $9,866,442 for the three months ended June 30, 2025, an improvement from $17,768,122 in the same period of 2024.
• For the six months ended June 30, 2025, the net loss was $27,425,907, down from $39,596,248 in the prior year period.
• Loss per common share for the six months ended June 30, 2025, was $0.86, compared to $1.31 for the same period in 2024.
• The company's cash and cash equivalents significantly decreased to $1,353,351 as of June 30, 2025, from $3,857,026 at December 31, 2024.
• Short-term investments also declined to $19,266,190 from $41,052,356 over the same period.
• Total current assets were $21,094,169 as of June 30, 2025, a substantial reduction from $45,795,843 at December 31, 2024.
• Research and development expenses decreased by $9,255,995 to $14,770,400 for the six months ended June 30, 2025, primarily due to the winding down of the REL-1017 studies.
• General and administrative expenses decreased by $4,110,907 to $13,669,342 for the six months ended June 30, 2025, mainly due to lower stock-based compensation.
• Relmada acquired Sepranolone for €3,000,000 and licensed NDV-01 for an upfront payment of $3,500,000 plus 3,017,420 shares and potential milestones up to $200 million.
• The Esmethadone (REL-1017) and psilocybin (REL-P11) development programs were terminated effective July 7, 2025, and May 12, 2025, respectively.
• Positive 6-month follow-up data for NDV-01 Phase 2 study in NMIBC showed a 90% complete response rate (19/21 patients) at 6 months, with no progression to muscle invasive disease or Grade 3+ adverse events.

Sentiment

Score: 3

Explanation: The sentiment is low due to the explicit 'going concern' warning and significant depletion of cash and short-term investments, which overshadow the positive clinical data for NDV-01 and the strategic pipeline diversification. While R&D costs decreased, the overall financial stability is severely compromised, indicating high risk.

Positives

• Net loss significantly decreased for both the three and six months ended June 30, 2025, compared to the prior year periods, indicating improved cost management.
• Research and development expenses decreased by approximately $9.26 million for the six months ended June 30, 2025, primarily due to the wind-down of the REL-1017 studies.
• General and administrative expenses decreased by approximately $4.11 million for the six months ended June 30, 2025, largely due to reduced stock-based compensation.
• Positive 6-month follow-up data from the Phase 2 study of NDV-01 for non-muscle invasive bladder cancer (NMIBC) showed a 90% complete response rate (19/21 patients) at 6 months.
• NDV-01 Phase 2 data indicated no progression to muscle invasive disease, no radical cystectomies, and no Grade 3 or higher treatment-related adverse events, suggesting a favorable safety profile.
• The acquisition of Sepranolone and the licensing of NDV-01 diversify the company's pipeline into new therapeutic areas with significant market potential.
• Sepranolone has an extensive safety database from over 335 participants and showed promising efficacy signals in Tourette Syndrome, including a 28% reduction in tic severity (YGTSS) and improved quality of life.
• The company possesses a substantial and growing intellectual property portfolio for both Sepranolone (over 40 patents, coverage beyond 2030) and NDV-01 (over 10 patents, coverage beyond 2038).

Negatives

• The company has incurred significant losses and negative cash flows from operations since inception, with an accumulated deficit of approximately $668.3 million as of June 30, 2025.
• A substantial doubt exists about the company's ability to continue as a going concern due to insufficient liquidity to sustain operations for one year.
• Cash and cash equivalents decreased significantly to $1,353,351 at June 30, 2025, from $3,857,026 at December 31, 2024.
• Short-term investments decreased substantially to $19,266,190 at June 30, 2025, from $41,052,356 at December 31, 2024.
• The Esmethadone (REL-1017) program, a previous key focus, was terminated effective July 7, 2025, following a 2024 setback.
• The psilocybin (REL-P11) development program was also terminated effective May 12, 2025.
• The company received a Nasdaq non-compliance notice for its minimum bid price and, despite transferring to the Nasdaq Capital Market, requires an extension until January 19, 2026, to regain compliance.

Risks

• The company has incurred significant losses and negative cash flows from operations since inception and expects to incur additional losses, raising substantial doubt about its ability to continue as a going concern.
• There is no assurance that the company will be able to secure additional financing, or if available, that it will be sufficient to meet its needs or on favorable terms.
• The company is dependent on the successful completion of research and development, and there is no assurance that any product will be approved or commercially viable.
• The company is subject to risks common to the biotechnology industry, including dependence on collaborative arrangements, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, and compliance with FDA and other governmental regulations.
• There is no assurance that the company will be able to regain or maintain compliance with Nasdaq's minimum bid price requirement, which could lead to delisting.
• The company has no commercial products or sales/marketing infrastructure and does not anticipate generating revenues for the foreseeable future.

Future Outlook

Relmada Therapeutics is focused on advancing novel and differentiated therapeutic solutions, addressing unmet medical needs, and prioritizing programs with substantial commercial potential. The company aims to leverage its development expertise, diversify its pipeline, and concentrate resources on midto late-stage programs with a clear path to commercialization. Key anticipated milestones include nine-month and twelve-month data from the NDV-01 Phase 2 NMIBC study in the second half and year-end 2025, respectively, followed by NDV-01 US IND clearance and initiation of Sepranolone clinical trial in Prader-Willi Syndrome in the first half of 2026. The company intends to actively monitor its bid price to regain Nasdaq compliance by January 19, 2026.

Management Comments

• Management and the Board of Directors have implemented an enhanced approach aimed at maximizing shareholder value, focusing on innovation, addressing unmet medical needs, large market opportunities, and intellectual property protection.
• The company substantially redesigned its development programs following a comprehensive strategic review in late 2024 and early 2025, concluding that the most promising path to create shareholder value was to leverage extensive drug development expertise and clinical operations capabilities by acquiring new development candidates.
• The company accelerated ongoing efforts to augment its development pipeline while diversifying its risk, which culminated in the licensing of NDV-01 and the acquisition of Sepranolone.
• Management is currently evaluating the size and scope of any subsequent operations and clinical trials that will affect the timing to obtain the required funding of future operations.
• The company intends to actively monitor its bid price during the Compliance Period and intends to take all reasonable measures available to regain compliance with the requirements for continued listing on the Nasdaq Capital Market.

Industry Context

Relmada Therapeutics operates in the highly competitive and rapidly evolving biotechnology industry, specifically focusing on clinical-stage drug development. The company's strategic shift to acquire new development candidates like NDV-01 (for NMIBC, addressing the global BCG shortage) and Sepranolone (for neurological disorders like Prader-Willi and Tourette Syndromes, targeting excessive GABAergic activity) reflects a pivot towards high-unmet-need areas and pipeline diversification. This move is common for clinical-stage biotechs seeking to de-risk their portfolios after setbacks in lead programs, aiming for assets with clearer paths to commercialization and strong intellectual property. The NMIBC market is experiencing a significant shift due to the BCG shortage, making novel therapies like NDV-01 particularly relevant. Similarly, neurosteroids for neurological disorders represent an emerging area of interest.

Comparison to Industry Standards

• NDV-01's Phase 2 data showing a 90% complete response rate at 6 months is presented as comparable to or better than Bacillus Calmette-Gurin (BCG), which is a standard of care for non-muscle invasive bladder cancer (NMIBC). This suggests a competitive efficacy profile against established treatments, especially given the ongoing global BCG shortage.
• Sepranolone's Phase 2a results, demonstrating a 28% reduction in tic severity (YGTSS) and improved quality of life in Tourette Syndrome, are described as 'competitive tic reduction' compared to standard of care. While specific comparative data against other companies' Tourette Syndrome drug candidates (e.g., Neurocrine Biosciences' Ingrezza or other investigational GABAergic modulators) are not provided, the favorable safety profile with no CNS off-target effects is a positive differentiator in the neurosteroid space.
• The company's accumulated deficit of over $668 million and the 'going concern' warning are significant financial indicators that place Relmada at a higher risk profile compared to more financially stable, revenue-generating biotechnology companies or those with later-stage, de-risked assets.

Corporate Governance

Legal Proceedings

• The company is currently not aware of any legal proceedings or potential claims against it whose outcome would be likely, individually or in the aggregate, to have a material adverse effect on its business, financial condition, operating results, or cash flows.

Related Party Transactions

• Dr. Paolo Manfredi, co-inventor of REL-1017, and Dr. Marco Pappagallo are affiliated with Arbormentis, LLC, from whom the company acquired development and commercial rights to a psilocybin program (now terminated).
• The company assumed an obligation to pay a third party (Dr. Charles E. Inturrisi and Dr. Paolo Manfredi) royalty payments and milestone payments related to a prior acquisition, and continues to pay $45,000 every three months under the Inturrisi/Manfredi License Agreement (esmethadone program, now terminated).

Stakeholder Impact

• **Shareholders**: Face significant dilution risk from potential future equity raises and the ongoing Nasdaq minimum bid price compliance issue. The 'going concern' warning indicates substantial financial risk. However, the positive NDV-01 clinical data and new pipeline acquisitions offer potential upside if financing is secured and development progresses.
• **Employees**: The company's strategic shift and program terminations (Esmethadone, Psilocybin) could impact job security for those involved in those programs, though new acquisitions might create new roles. Stock-based compensation remains a significant part of employee remuneration.
• **Customers (Future Patients)**: The termination of Esmethadone and Psilocybin programs means these potential therapies will not be available. However, the advancement of NDV-01 for NMIBC and Sepranolone for neurological disorders offers new treatment possibilities for patients in those areas.
• **Suppliers/Creditors**: The 'going concern' warning and declining cash position increase credit risk for suppliers and creditors, potentially affecting payment terms or willingness to engage in future business.

Next Steps

• Monitor NDV-01 Nine-month data from ongoing Phase 2 NMIBC Study (2nd Half 2025).
• Monitor NDV-01 Twelve-month data from ongoing Phase 2 NMIBC Study (Year end 2025).
• Seek NDV-01 United States Investigative New Drug (IND) clearance (1st Half 2026).
• Initiate Sepranolone clinical trial in Prader-Willi Syndrome (1st Half 2026).
• Actively monitor the company's bid price and take measures to regain Nasdaq compliance by January 19, 2026.
• Evaluate and secure additional financing through equity, debt, loans, or strategic collaborations/licensing agreements.

Key Dates

Recommendation

While the company reported a reduced net loss and positive early clinical data for its new lead candidate NDV-01, the explicit 'going concern' warning and significant depletion of cash and short-term investments present a severe financial risk. The strategic pivot and new pipeline acquisitions are positive, but the ability to fund these programs and sustain operations is highly uncertain. A 'hold' recommendation acknowledges the potential upside from the new pipeline and clinical progress, but strongly cautions investors about the immediate and substantial liquidity risks and the need for successful capital raises to avoid further financial distress or delisting. This is a high-risk, high-reward scenario, suitable only for investors with a high tolerance for risk and a belief in the company's ability to secure necessary funding.

Keywords

Biotechnology, Clinical-stage, Drug development, NMIBC, Non-muscle invasive bladder cancer, NDV-01, Sepranolone, Prader-Willi Syndrome, Tourette Syndrome, Neurosteroid, GABAergic activity, SEC filing, 10-Q, Financial results, Nasdaq compliance, Going concern, Pipeline diversification